For research use only. Not for therapeutic Use.
ANT431（Cat No.:I022221）is a small molecule inhibitor that selectively targets and inhibits the activity of a specific protein involved in cellular processes like signal transduction and gene regulation. It has been investigated for its potential in treating various cancers, particularly by disrupting pathways that allow tumor cells to proliferate and survive. ANT431 is also being studied for its ability to modulate immune responses, which may have applications in autoimmune diseases or inflammatory conditions. Clinical trials are ongoing to assess its safety, efficacy, and potential therapeutic benefits in oncology and immunology.
| Catalog Number | I022221 |
| CAS Number | 1639972-90-9 |
| Synonyms | ANT431; ANT 431; ANT-431 |
| Molecular Formula | C9H7N3O4S2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 5-(pyridin-3-ylsulfonylamino)-1,3-thiazole-4-carboxylic acid |
| InChI | InChI=1S/C9H7N3O4S2/c13-9(14)7-8(17-5-11-7)12-18(15,16)6-2-1-3-10-4-6/h1-5,12H,(H,13,14) |
| InChIKey | OLGRJQGVXXCIMN-UHFFFAOYSA-N |
| SMILES | C1=CC(=CN=C1)S(=O)(=O)NC2=C(N=CS2)C(=O)O |
| Reference | 1: Leiris S, Coelho A, Castandet J, Bayet M, Lozano C, Bougnon J, Bousquet J, Everett M, Lemonnier M, Sprynski N, Zalacain M, Pallin TD, Cramp MC, Jennings N, Raphy G, Jones MW, Pattipati R, Shankar B, Sivasubrahmanyam R, Soodhagani AK, Juventhala RR, Pottabathini N, Pothukanuri S, Benvenuti M, Pozzi C, Mangani S, De Luca F, Cerboni G, Docquier JD, Davies DT. SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model. ACS Infect Dis. 2019 Jan 11;5(1):131-140. doi: 10.1021/acsinfecdis.8b00246. Epub 2018 Nov 30. PubMed PMID: 30427656; PubMed Central PMCID: PMC6332448. |
